Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

set by lower apatorsen manufacturing costs due to the timing of manufacturing activities.
  • Net loss for the second quarter and six months ended June 30, 2013 was $8.4 million, or $0.57 per diluted common share, and $15.1 million, or $1.03 per diluted common share, respectively. Net loss for the second quarter and six months ended June 30, 2012 was $4.2 million, or $0.29 per diluted common share, and $11.1 million, or $0.89 per diluted common share, respectively. The net loss in the six months ended June 30, 2013 included a non-cash gain on revaluation of the warrant liability of $2.3 million. 
  • The Company had $57.0 million in cash, cash equivalents and short-term investments as of June 30, 2013, compared to $75.4 million as of December 31, 2012.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 - $50 million.
  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of June 30, 2013 will be sufficient to fund its currently planned operations into 2015.
  • At August 8, 2013, The Company had 14,680,395 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended June 30,Six months ended June 30,2013201220132012Collaboration revenue

    $
    ,340$
    2,429$
    ,416$
    3,745Operating expenses:  Research and development

    13,2636,32624,11811,408  General and administrative

    2,4732,0474,9733,784Total operating expenses

    15,7368,37329,09115,192Loss from operations

    (9,396)(5,944)(17,675)(11,447)  Other income (expense)

    9761,7292,558372Net loss

    $
    (8,420)$
    (4,215)$
    (15,117)$
    (11,075)Basic and diluted net loss per share

    $
    (0.57)$
    (0.29)$
    (1.03)$<
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... BOSTON , May 29, 2015 /PRNewswire/ ... custom automation, and contract manufacturing, and Vaxxas , ... drug delivery technology, have been named winners of the ... Nanopatch Jet Coating Instrument , an advanced technology platform ... development.  The award was announced last evening at the ...
    (Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
    (Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) and ... have entered into a clinical trial collaboration to evaluate ... immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... The planned study will assess the combination as a ... The Phase I study is expected to establish the ...
    Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
    ... U.S. Food and Drug Administration today advised consumers ... not to use the product. FDA warns that ... active pharmaceutical ingredient sibutramine, a prescription-only drug which ... the product label and could harm consumers, especially ...
    ... 8 Synapse Biomedical Inc ... U.S. Food and Drug Administration (FDA) designation of the ... Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis ( ... experiencing chronic hypoventilation and has now submitted for Humanitarian ...
    Cached Medicine Technology:FDA: Potentially Harmful Stimulant Found in Slimming Beauty Capsules 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 3Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 4
    (Date:5/29/2015)... 2015 A group of doctors have discovered ... national effort to teach this “new math” to children in ... been “sickened” by the recent implementation of Common Core Math ... it, Common Core is now a reality in children’s classrooms ... are now seeking ways to improve common core math training ...
    (Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
    (Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
    (Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... is giving patients a long-lasting impression on what ... provider of VisitandCare.com is on a mission to revolutionize ... cosmetic dentistry with a high-class Wellness & Spa. ... of the world’s most successful medical tourism agencies ...
    (Date:5/29/2015)... May 29, 2015 As spring has ... Metro series outdoor saunas have increased in popularity as ... and work at summer cottages. While a perennial ... in summer projects a few weeks earlier than usual. ... with smaller lot sizes tend to prefer the Patio ...
    Breaking Medicine News(10 mins):Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
    ... therapy (ECT) helps patients with severe depression who don't ... often in the earlier stages of the illness, ... ,"Electroconvulsive therapy has been shown to be ... persistent and severe depression, bipolar disorder, and schizophrenia," writes ...
    ... sudden outbreak of disease has claimed a tenth of Idahos ... fish food and labor. , The outbreak of ... in southwestern Idaho- the state Department of Fish and Game ... the region and official say that it probably resulted when ...
    ... Monday opposed introduction of sex education in Kashmir schools ... ,Addressing a media conference here, Asiya Andrabi, the DeM ... nefarious Indian designs to perpetuate obscenity and vulgarity in ... schools." ,Andrabi, branded as a hardliner, said ...
    ... in regard to doctor-patient ratio in various State Government ... varies from case to case depending upon various factors ... of patient-care required i.e. indoor/outdoor. According to the Medical ... works out to 1:1722. ,The patient ...
    ... company Advanced Cell Technology, is obviously thrilled with ... repair arteries and regenerate blood. , According to ... proceed on to hearts and arteries of ... have devised a straightforward way to make blood vessel precursor ...
    ... are 73557. There are 22273 numbers of doctors at ... on March 2006. As on 1.1.2007, total numbers of beds ... beds are available in urban government hospitals including Community Health ... of CHCs are located in government buildings. As on March ...
    Cached Medicine News:Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2Health News:Disease Outbreak Claims Trout From Idaho Hatchery 2Health News:Hemangioblasts Aiding Eye Damage Repair 2
    ... Disc is a Hand Assisted Laparoscopic Surgery ... the surgeons hand may facilitate the procedure, ... has applications in colorectal, urological and general ... extracorporeal extension of pneumoperitoneum and abdominal access ...
    ... SleepStyle 200 series offers a range ... models. The design delivers therapy to ... features promote results in commercial and ... strongest differentiator in the SleepStyle 200 ...
    ... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
    ... S6 Lightweight II CPAP has sound ... that maintains consistent pressure. The backlit ... the settings easy, and the interface ... adjustments is simple. This CPAP device ...
    Medicine Products: